APRINOIA Therapeutics

APRINOIA Therapeutics is a clinical-stage biotechnology company developing precision diagnostics and targeted therapeutics for neurodegenerative diseases, based in Cambridge, Massachusetts. The organization focuses on creating novel PET imaging tracers and treatments targeting toxic protein aggregates, such as tau and alpha-synuclein, associated with Alzheimer’s disease and Progressive Supranuclear Palsy. Operating with a workforce of 72 employees, the enterprise has financed its clinical research and development pipeline through multiple venture capital rounds, including an $11 million Series B and a $40 million Series C financing. The company previously planned to go public via a special purpose acquisition company merger at a $280 million valuation, and it maintains strategic licensing and partnership agreements with prominent industry entities including Biogen, Celgene, KTB Network, and Wilbur Ross. APRINOIA Therapeutics was originally founded in the year 2015 by Ming-Kuei Jang.